JS207 / Shanghai Junshi Biosci  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
JS207 / Shanghai Junshi Biosci
NCT06022250: The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor

Not yet recruiting
1
162
RoW
JS207
Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH
Advanced Malignant Tumor
09/25
03/26

Download Options